Company profile

PharmaBiome AG

PharmaBiome develops a pipeline for the use of beneficial gut bacteria as an innovative, standardized and safe therapeutic product to treat diseases caused by functional deficiencies in the microbiome (i.e. gut flora), with an initial focus on ulcerative colitis (UC). Using its proprietary technology platform including isolation, cultivation and rational assembly of intestinal bacterial mixtures, PharmaBiome develops tailored microbiome products. The flexibility and speed of development are a unique advantage to penetrate the multibillion markets of untreatable intestinal diseases.

More news about PharmaBiome AG

08.07.2020 11:28

PharmaBiome secures CHF 1.75 million bridge funding

Please login or
register to use the
awards follow feature
05.03.2020 09:28

Die Finalisten des ZKB Pionierpreis Technopark stehen fest

Please login or
register to use the
awards follow feature
21.01.2020 16:05

BaseLaunch accelerator nominates 4 startups for phase 2

Please login or
register to use the
awards follow feature
08.01.2020 11:51

ZKB Pionierpreis Technopark: Zehn Firmen kämpfen um 100‘000 Franken

Please login or
register to use the
awards follow feature
04.10.2019 12:05

A new cohort joins the BaseLaunch accelerator

Please login or
register to use the
awards follow feature
20.05.2019 09:41

Drawing closer to the finale of the de Vigier Award

Please login or
register to use the
awards follow feature
23.03.2018 11:53

Ein Startup gewinnt den Spark Award

Please login or
register to use the
awards follow feature
14.06.2016 14:41

130‘000 Franken für PharmaBiome

Please login or
register to use the
awards follow feature
06.04.2016 16:45

Venturelab presents the 20 Venture leaders of 2016

Please login or
register to use the
awards follow feature
PharmaBiome AG

Founded
2015

Kanton
Zürich


LinkedIn

Twitter
@pharmabiome

Homepage

rss